Full-Time
Account Executive / Regional Specialty Infusion Sales
Updated on 8/20/2026
BrightSpring Health Services
10,001+ employees
Home-based health services and pharmacy solutions
Compensation Overview
$115k - $130k/yr
Phoenix, AZ, USA
In Person
Must reside in, or be within commuting distance of, Phoenix.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to BrightSpring Health Services
See people who can refer or advise you
- A four-year college degree in business or a healthcare-related field, or equivalent work experience.
- A minimum of four years of pharmaceutical or healthcare sales experience.
- Three to five years of experience in infusion services or other related healthcare product or service industries is preferred.
- Candidates must be comfortable with physicians as the main call points.
- Candidates must be able to present products and services in a professional manner.
- Knowledge of infusion service procedures and reimbursement policies is preferred.
- Candidates must have excellent communication, planning, and organizational skills.
- A valid driver's license and auto insurance are required.
- Candidates must meet company standards for driving record and driver age.
- Aggressively sell and market infusion therapy to existing and potential referral sources to achieve established monthly, quarterly, and annual revenue targets.
- Identify and develop relationships with regional sales targets, including specialty physicians who prescribe targeted medications.
- Conduct in-service training seminars and represent the company at local, regional, and national trade shows and conventions.
- Create and carry out specific sales and market development plans in concert with company goals and objectives.
- Provide regular feedback to local and corporate management regarding sales activity and success in market development.
- Represent the company within the healthcare community with professional decorum and respect for the patient care process.
- Develop quarterly business plans and maintain customer relationship management records, such as Salesforce.com.
- Registered Nurse and home healthcare experience.
- Three to five years of experience in infusion services or other related healthcare product or service industries.
- Knowledge of infusion service procedures and reimbursement policies.
BrightSpring Health Services delivers home and community-based health services for people with complex or chronic needs, organized into two segments: Pharmacy and Provider. The Pharmacy segment provides specialty, infusion, and community pharmacy services to patients with complex conditions. The Provider segment offers behavioral health, home health, hospice care, and services for individuals with intellectual and developmental disabilities. The company runs an integrated care model through a network of pharmacies and providers to support a continuum of care that includes clinical services, care coordination, and in-home support. Revenue comes from Medicare, Medicaid, and private insurance, reflecting reimbursement across public and private payers. The goal is to coordinate pharmacy and in-home health services to improve access, continuity, and outcomes for patients and to serve managed care organizations with a complete care solution.
Company Size
10,001+
Company Stage
Post IPO Equity
Headquarters
Louisville, Kentucky
Founded
1974
Get referred to BrightSpring Health Services
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 23% to $3.87 billion, with EBITDA up 44%.
- Management raised 2026 EBITDA guidance to $820 million–$845 million on July 31, 2026.
- Leverage fell to 2.15x, and S&P and Moody’s upgraded BrightSpring’s credit.
What critics are saying
- IRA pricing cuts reduced Home and Community Pharmacy 8% in Q2 2026.
- Management expects roughly $200 million 2026 IRA pressure, crushing pharmacy margin leverage.
- PharMerica’s breach settlement and security spending drain cash during Amedisys integration.
What makes BrightSpring Health Services unique
- BrightSpring combines specialty pharmacy with home-based provider services across complex chronic care.
- Its 2026 portfolio reached 153 ultra-narrow drugs, strengthening limited-distribution access advantages.
- Amedisys and LHC branches deepen BrightSpring’s local density in home health and hospice.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↓ -10%1 year growth
↓ -10%2 year growth
↓ -10%BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.
Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.
BrightSpring Health Services exceeded Wall Street expectations in Q2, delivering revenue of $3.87 billion and adjusted earnings per share of $0.45, beating analyst estimates by 5.9% and 13% respectively. The company's Specialty and Infusion pharmacy business drove growth, with revenue up 30% and script growth of 31% year-over-year. CEO Jon Rousseau attributed the performance to new limited distribution drug launches and broad-based volume growth. However, segments like Home and Community Pharmacy faced challenges from customer exits and regulatory headwinds. The company raised its full-year revenue guidance to $15.26 billion at the midpoint, up 1.9% from previous guidance. Operating margin improved to 3.4%, compared to 1.5% in the prior-year quarter. Despite the strong results, the market reacted negatively, reflecting concerns about underlying business headwinds.
Micron Technology, BrightSpring Health Services, and Custom Truck One Source have emerged as standout profitable stocks based on strong net income ratios and growth prospects. The selection criteria included a Zacks Rank of #1, trailing 12-month sales and net income growth exceeding industry averages, and a net income ratio higher than the industry standard. Micron Technology, a global memory and storage provider, shows particularly impressive metrics with a 12-month net profit margin of 55.9%. The company's expected earnings growth rate for the current year stands at 791%. The screening process, using the Zacks Research Wizard, filtered more than 7,685 stocks down to just 13 that met all criteria. The net income ratio helps investors assess a company's ability to cover both operating and non-operating expenses with revenues.
BrightSpring Health Services shares fell 17.5% after reporting second-quarter results, despite beating expectations. The healthcare services provider posted revenue of $3.87 billion, up 23% year-on-year, whilst non-GAAP profit reached $0.45 per share, exceeding forecasts. The company also raised its full-year guidance. However, investors responded negatively in what appeared to be a "sell-the-news" reaction. The sell-off may stem from valuation concerns and stagnant profit margins despite rising sales, raising questions about the company's cost structure. The stock has experienced 18 movements greater than 5% over the past year. At $59.71 per share, BrightSpring trades 18.1% below its 52-week high of $72.91 from July, though it remains up 55.5% year-to-date.